Please login to the form below

Not currently logged in
Email:
Password:

MedImmune appoints Dr Anand Subramony

He joins from Novartis to take up drug delivery and device development role

AstraZeneca AZ MedImmune Anand SubramonyAstraZeneca's MedImmune unit has appointed Dr Anand Subramony as its new vice president of drug delivery and device development.

He joins the company's biopharmaceutical development unit from Novartis, whose Institutes for Biomedical Research he previously worked for in Cambridge, Massachusetts.

While at Novartis Dr Subramony established and headed company's novel delivery technologies and therapeutics group.

Prior to that he held leadership positions at Dr. Reddy's Laboratories in Bridgewater, New Jersey and Johnson & Johnson/Alza Corporation in Mountain View, California.

Dr Subramony will bring to MedImmune experience that includes drug-device combination products and a further boost to its focus on biologics delivery and device development.

13th March 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics